The roles of adjuvant inhaled and systemic corticosteroids in the treatment of pneumonia

Scott A. Helgeson, Joseph E. Levitt, Emir Festic


Cover Image

Community and health-care associated pneumonia remain leading causes of morbidity and mortality despite appropriate antibiotic therapy. The pneumonia-associated adverse outcomes are not only related to the infectious organism, but also to a dysfunctional host-immune response resulting in overwhelming inflammation. Use of systemic corticosteroids as adjuvant therapy in pneumonia remains controversial.  Multiple randomized clinical trials evaluating corticosteroids in patients with community acquired pneumonia have found discrepant results in terms of benefits and adverse effects. Although meta-analyses suggest potential benefits in a select group of patients with more severe pneumonia, the ideal timing, dose, route of delivery, duration, and patient selection remain to be established. Inhaled delivery of corticosteroids offer the potential advantage of providing therapeutic benefits directly to the lung, with minimal to no adverse systemic effects. A smaller body of literature suggests benefit of inhaled corticosteroids, with or without inhaled beta agonists, but future large scale clinical trials are needed to establish clinical benefit with inhaled delivery. 

J Nat Sci, 5(3):e553, 2019




HomeAbout JNSCI Privacy PolicyPeer ReviewPub Fee
Ads FeeAuthor Guidance 

©2019 Journal of Nature and Science (JNSCI), Los Angeles, CA, USA | ISSN 2377-2700 | Contact: editor@jnsci.org